Last reviewed · How we verify
combination with dopamine agonist cabergoline
Cabergoline is a dopamine agonist that stimulates dopamine D2 receptors to inhibit prolactin secretion from the anterior pituitary gland.
Cabergoline is a dopamine agonist that stimulates dopamine D2 receptors to inhibit prolactin secretion from the anterior pituitary gland. Used for Hyperprolactinemia (prolactin-secreting pituitary adenomas), Idiopathic hyperprolactinemia, Restless legs syndrome (RLS).
At a glance
| Generic name | combination with dopamine agonist cabergoline |
|---|---|
| Also known as | Cabergoline: Dostinex 0.5mg: MA number 32411.00.00 |
| Sponsor | Ludwig-Maximilians - University of Munich |
| Drug class | Dopamine agonist |
| Target | Dopamine D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Cabergoline binds to dopamine D2 receptors on lactotroph cells in the pituitary, mimicking dopamine's natural inhibitory effect on prolactin release. This leads to sustained suppression of elevated prolactin levels. The drug is long-acting due to its high receptor affinity and slow clearance, allowing for less frequent dosing compared to other dopamine agonists.
Approved indications
- Hyperprolactinemia (prolactin-secreting pituitary adenomas)
- Idiopathic hyperprolactinemia
- Restless legs syndrome (RLS)
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Postural hypotension
- Valvular heart disease (rare, long-term use)
Key clinical trials
- Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients (PHASE4)
- Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients
- Acute Application of Pegvisomant and Octreotide in Acromegaly (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: